Tevogen Bio Holdings Inc. announced plans to expand the target population for its treatment TVGN 489 to include patients aged 65 and older, enhancing its market potential in specialty pharmaceuticals.
When Amy Finkelstein, a Massachusetts Institute of Technology (MIT) researcher and MacArthur genius, evaluates another MacArthur genius, Jeff Brenner, who was initially made popular by another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback